Tarlatamab and Durvalumab Improve Survival in Extensive-Stage Small Cell Lung Cancer

The phase 3 DeLLphi-305 trial demonstrated that combining tarlatamab with durvalumab significantly improves both overall and progression-free survival in patients with extensive-stage small cell lung cancer. This finding marks an important advancement in treatment options for this aggressive cancer type.

Originally published by gnews